Literature DB >> 7351532

A comparison of the structural polypeptides of five strains of mumps virus.

M McCarthy, R T Johnson.   

Abstract

The polypeptide patterns of five strains of mumps virus have been compared under uniform electrophoresis conditions. These strains included the MJ and RW strains, recently isolated from human cerebrospinal fluid, the neuro-adapted Kilham strain and the chick embryo-adapted Enders and Jeryl Lynn strains. A similar pattern of polypeptides, featuring six common and virus-specific species, was obtained with purified virus grown in ovo, in hick embryo fibroblasts (CEF) or in Vero cells. These polypeptides have been designated VP1 (mol. wt. 200000), VP2 (mol. wt. 80000 or 75000), VP3 (mol. wt. 68000), VP4 (mol. wt. 58000), VP5 (mol. wt. 45000), VP6 (mol. wt. 39000). The virus glycoproteins were identified as VP2 and VP4; the nucleocapsid-associated proteins as VP1, VP3 and VP5. Additional polypeptides occurring both in uninfected Vero cells and in uninfected CEFs appeared in polypeptide profiles of purified mumps virus preparations, and could not be designated virus-specific polypeptides. Alhtough strain differences were minimal, we did observe (1) an extra protein, nucleocapsidassociated, in patterns from the chick-adapted Enders strain of mumps virus and (2) strain-dependent variability in the size of VP2.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7351532     DOI: 10.1099/0022-1317-46-1-15

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  14 in total

1.  A novel P/V/C gene in a new member of the Paramyxoviridae family, which causes lethal infection in humans, horses, and other animals.

Authors:  L F Wang; W P Michalski; M Yu; L I Pritchard; G Crameri; B Shiell; B T Eaton
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

2.  Hemagglutinin-neuraminidase glycoprotein as a determinant of pathogenicity in mumps virus hamster encephalitis: analysis of mutants selected with monoclonal antibodies.

Authors:  A Löve; R Rydbeck; K Kristensson; C Orvell; E Norrby
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

3.  Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis.

Authors:  J S Wolinsky; M N Waxham; A C Server
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

4.  Functional properties and genetic relatedness of the fusion and hemagglutinin-neuraminidase proteins of a mumps virus-like bat virus.

Authors:  Nadine Krüger; Markus Hoffmann; Jan Felix Drexler; Marcel Alexander Müller; Victor Max Corman; Christian Sauder; Steven Rubin; Biao He; Claes Örvell; Christian Drosten; Georg Herrler
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

5.  Interaction of viral envelope glycoproteins with fibronectin.

Authors:  I Julkunen; A Hautanen; J Keski-Oja
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

6.  Differentiation of mumps virus strains with monoclonal antibody to the HN glycoprotein.

Authors:  A C Server; D C Merz; M N Waxham; J S Wolinsky
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

7.  Enzyme-linked immunosorbent assay compared with neutralization tests for evaluation of live mumps vaccines.

Authors:  H Sakata; M Hishiyama; A Sugiura
Journal:  J Clin Microbiol       Date:  1984-01       Impact factor: 5.948

8.  Accumulation of altered viral nucleocapsids in mumps virus--persistently infected cell cultures.

Authors:  O G Andzhaparidze; N N Bogomolova; V D Lotte
Journal:  Arch Virol       Date:  1983       Impact factor: 2.574

9.  The structural polypeptides of avian paramyxoviruses.

Authors:  D J Alexander; M S Collins
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

10.  The Amino Acid at Position 8 of the Proteolytic Cleavage Site of the Mumps Virus Fusion Protein Affects Viral Proteolysis and Fusogenicity.

Authors:  Sarah Hüttl; Markus Hoffmann; Torsten Steinmetzer; Christian Sauder; Nadine Krüger
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.